Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3923868 in mild asthma with experimental rhinovirus infection
NCT05398198Phase 1Completed
- Sponsor
- GSK
- Start
- Jun 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in human rhinovirus infection comparing GSK3923868 with Placebo (2 arms). Primary endpoint: Area under curve of change from baseline in total lower respiratory tract symptoms score at Day 15. Started Jun 2022; status: completed.
02
Drugs
GSK3923868
03
Conditions
human rhinovirus infection
Beyond the preview
Go deeper on NCT05398198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05398198.